Celularity IPO
Celularity is a biotechnology company developing cellular therapies using placental-derived cells for cancer, infectious diseases, and degenerative disorders. The company focuses on allogeneic cell therapies that can be manufactured at scale. Investors monitor Celularity's clinical trial progress and regulatory milestones in the competitive cell therapy market.
What We Know
Celularity went public in 2021 through a merger with GX Acquisition Corp, a SPAC. The company raised capital to advance its pipeline of placental cell-derived therapies through clinical trials. The stock has faced typical biotech volatility as investors track clinical trial results and regulatory progress. As a clinical-stage biotech company, Celularity's stock performance is closely tied to pipeline developments and trial outcomes. The company continues to advance multiple programs through various stages of clinical development, with investors watching for data readouts and potential partnerships.
Frequently Asked Questions
Has Celularity had an IPO?
Yes, Celularity went public in 2021 through a SPAC merger with GX Acquisition Corp. The company has been publicly traded since then.
When is the Celularity IPO date?
Celularity already completed its public offering in 2021, so there is no upcoming IPO. The stock trades on public markets.
How can I buy Celularity stock?
You can purchase Celularity stock through any brokerage account as it's publicly traded under ticker CELU. The stock is available on major exchanges.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts